Physician profile
Sally Miller
NPI 1669432399
$3,801.94
in general payments reported to CMS, 2019-2025
25 companies · $37.44 in 2025
The $37.44 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,062 · 2022: $662 · 2023: $24.96 · 2024: $15.91 · 2025: $37.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.71 | 2021-2022 | |
| Janssen Biotech, INC. | $568.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.19 | 2021 | |
| Qol Medical, LLC | $265.89 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $265.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.58 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $138.81 | 2021-2022 | |
| Vivus LLC | $125.31 | 2021 | |
| Ironwood Pharmaceuticals, INC | $123.52 | 2021 | |
| Nestle Healthcare Nutrition INC. | $122.33 | 2021 | |
| Pfizer INC. | $104.49 | 2021 | |
| Novo Nordisk INC | $103.39 | 2021 | |
| Gilead Sciences, INC. | $98.28 | 2021 | |
| Evoke Pharma, INC. | $66.41 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $37.70 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $37.44 | 2025 | Renal - Pd |
| Daiichi Sankyo INC. | $35.18 | 2021 | |
| Horizon Therapeutics Plc | $33.50 | 2021 | |
| Sandoz INC. | $24.96 | 2023 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $20.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2022 | |
| Celgene Corporation | $17.25 | 2021 | |
| Merck Sharp & Dohme LLC | $16.59 | 2022 | |
| Baxter Healthcare | $15.91 | 2024 | Renal - Pd |
| Redhill Biopharma INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.